Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maxine Bauzon

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Frontiers in Immunology|March 8, 2014
Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapyMaxine Bauzon, Terry Hermiston
Current Opinion in Molecular Therapeutics|August 7, 2008
Exploiting diversity: genetic approaches to creating highly potent and efficacious oncolytic virusesMaxine Bauzon, Terry W Hermiston
Advances in Virology|February 8, 2012
Oncolytic viruses: the power of directed evolutionMaxine Bauzon, Terry W Hermiston
The Journal of Trauma and Acute Care Surgery|June 19, 2023
Rapid clearing CT-001 restored hemostasis in mice with coagulopathy induced by activated protein CDerek S Sim, Cornell R Mallari, Maxine Bauzon, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 3, 2003
Multigene expression from a replicating adenovirus using native viral promotersMaxine Bauzon, Daniel Castro, Michael Karr, et al.
Molecular Therapy Oncolytics|March 28, 2017
OvAd1, a Novel, Potent, and Selective Chimeric Oncolytic Virus Developed for Ovarian Cancer by 3D-Directed EvolutionIrene Kuhn, Maxine Bauzon, Nicola Green, et al.
Thrombosis Research|May 31, 2022
CT-001 is a rapid clearing factor VIIa with enhanced clearance and hemostatic activity for the treatment of acute bleeding in non-hemophilia settingsDerek S Sim, Cornell R Mallari, John M Teare, et al.
Oncoimmunology|March 26, 2019
Maytansine-bearing antibody-drug conjugates induce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cellsMaxine Bauzon, Penelope M Drake, Robyn M Barfield, et al.
Research and Practice in Thrombosis and Haemostasis|July 15, 2021
In vitro characterization of CT-001-a short-acting factor VIIa with enhanced prohemostatic activityDerek S Sim, Cornell R Mallari, John M Teare, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 17, 2007
Development and validation of a robust and versatile one-plasmid regulated gene expression systemPaul Szymanski, Peter J Kretschmer, Maxine Bauzon, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Frontiers in Immunology|March 8, 2014
Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapyMaxine Bauzon, Terry Hermiston
Current Opinion in Molecular Therapeutics|August 7, 2008
Exploiting diversity: genetic approaches to creating highly potent and efficacious oncolytic virusesMaxine Bauzon, Terry W Hermiston
Advances in Virology|February 8, 2012
Oncolytic viruses: the power of directed evolutionMaxine Bauzon, Terry W Hermiston
The Journal of Trauma and Acute Care Surgery|June 19, 2023
Rapid clearing CT-001 restored hemostasis in mice with coagulopathy induced by activated protein CDerek S Sim, Cornell R Mallari, Maxine Bauzon, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 3, 2003
Multigene expression from a replicating adenovirus using native viral promotersMaxine Bauzon, Daniel Castro, Michael Karr, et al.
Molecular Therapy Oncolytics|March 28, 2017
OvAd1, a Novel, Potent, and Selective Chimeric Oncolytic Virus Developed for Ovarian Cancer by 3D-Directed EvolutionIrene Kuhn, Maxine Bauzon, Nicola Green, et al.
Thrombosis Research|May 31, 2022
CT-001 is a rapid clearing factor VIIa with enhanced clearance and hemostatic activity for the treatment of acute bleeding in non-hemophilia settingsDerek S Sim, Cornell R Mallari, John M Teare, et al.
Oncoimmunology|March 26, 2019
Maytansine-bearing antibody-drug conjugates induce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cellsMaxine Bauzon, Penelope M Drake, Robyn M Barfield, et al.
Research and Practice in Thrombosis and Haemostasis|July 15, 2021
In vitro characterization of CT-001-a short-acting factor VIIa with enhanced prohemostatic activityDerek S Sim, Cornell R Mallari, John M Teare, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 17, 2007
Development and validation of a robust and versatile one-plasmid regulated gene expression systemPaul Szymanski, Peter J Kretschmer, Maxine Bauzon, et al.
Pageof 3